Healthcare
Poly Medicure bets on new facilities, products to double international business: MD
The company's international business contributed ₹1,280.2 crore in FY26, accounting for nearly 68% of the company's total revenue of ₹1,875.3 crore. It expects the next phase of growth to be supported by two upcoming manufacturing facilities, a pipeline of more than 50 products, and a sharper focus on direct-market operations across key overseas geographies.
Global smart money can't get enough of India's next growth story
Global private equity firms are expanding beyond hospitals into India's broader healthcare ecosystem, with Warburg Pincus, TA Associates, Bain Capital and CVC Capital in talks to acquire a 25% stake in Agappe Diagnostics at a valuation of ₹3,000–3,200 crore.
Antibiotic resistance emerging as major threat to surgical care: Experts
Antimicrobial resistance now challenges routine surgical procedures and increases infection risks. Surgeons warn that losing effective antibiotics undermines decades of progress in safe surgery. Hospitals are adopting stricter antibiotic stewardship and infection prevention measures. Multidrug-resistant organisms pose a significant challenge to treating post-operative infections effectively. Preserving antibiotic effectiveness is a shared responsibility for future generations.
HCG uses AI, patient data to personalise cancer treatment: BS Ajaikumar, founder
Healthcare Global Enterprises is using artificial intelligence and patient data. Algorithms are being developed to personalise cancer treatment and improve outcomes. The company analyses clinical and genomic data to classify patients for better decisions. HCG partnered with Accenture to enhance its AI research capabilities.
Govt to plug regulatory gaps in drug deals
Authorities discovered drugmakers hid licence cancellations to obtain supply orders. The government now mandates states display this information on their websites. This data will be shared monthly with the Central Drugs Standard Control Organisation. The move aims to ensure quality medicines reach hospitals and consumers. Timely disclosure strengthens monitoring between the Centre and states.
GA-Renova & CCA in race to buy American oncology: Siemens Healthineers looking to exit non-core business for Rs 1,500 crore
Two prominent players are in the running to purchase American Oncology Institute from Siemens Healthineers. One of the potential buyers is General Atlantic in collaboration with Renova Hospitals, while the other contender is Raj Mantena's Cancer Centers of America. Siemens Healthineers initially acquired this cancer network as part of a larger strategic agreement. The completion of the sale is anticipated by mid-August.
IHH hospitals in India, Singapore saw fewer patients from Middle East due to war
IHH Healthcare hospitals in India saw fewer patients from the UAE and Saudi Arabia. Singapore hospitals also faced impacts from the ongoing Middle East conflict. This regional instability creates significant uncertainty for businesses globally. Soaring energy prices and disrupted supply chains are major concerns. IHH previously stated its diversified footprint mitigated earlier geopolitical impacts.
Govt steps up efforts to curb 'irrational' drugs with crackdown on FDCs not part of official database
The government plans to act against drugmakers with unlisted products. This move aims to stop the sale of irrational fixed-dose combinations. Expert committees suggest unapproved formulations could face license cancellation. Previous government directions failed to ensure lasting compliance with regulations. A new comprehensive framework is now being developed to resolve this issue.
Opportunity worth $35 billion for medtech sector in India by 2030: Bain & Co
India's medtech sector presents a USD 35 billion opportunity by 2030. Exports are projected to reach USD 8 billion, growing over twenty percent annually. The nation is becoming a prominent access-led innovator in the Asia-Pacific region. This growth is driven by increasing healthcare demand and a developing innovation ecosystem. India's medical device exports reached USD 4 billion in FY25.
Fortis Healthcare board okays extending MD & CEO Ashutosh Raghuvanshi's tenure by 2 years
Fortis Healthcare's board has approved Ashutosh Raghuvanshi's reappointment as Managing Director. His new term will commence on March 19, 2027, for a period of two years. This reappointment follows the conclusion of his current tenure on March 18, 2027. The board cited his expertise and role in the company's growth for this decision.
RECENT NEWS
- PHC Mogla brings healthcare closer to Rajouri's remote villages
- Pedro Pascal talks about Reed Richards and Dr Doom’s connection
- David Jonsson welcomed by Winston Duke for 'Black Panther 3'
- DMK demands immediate NEET ban, seeks probe into Jantar Mantar violence
- Katrina set to make her comeback with 'Spirit'? Fact Check
